股票代码：300016 股票简称：北陆药业 公告编号：2024-050 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 2024年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求（2022年修订）》和《深圳证券交易所上市公司自律监管指引第2号—创业板上 市公司规范运作》有关规定，现将公司2024年半年度募集资金存放与使用情况说 明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意北京北陆药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2020〕2810号）核准，公司 向社会公开发行面值不超过人民币500,000,000.00元的可转换公司债券。根据《北 京北陆药业股份有限公司向不特定对象发行可转换公司债券发行公告》，公司债 券发行面值50,000万元，每张面值为人民币100元，共计500万张，发行价格为100 元/张。扣除与本次发行有关的费用10,775, ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥473.93 million, representing an increase of 8.20% compared to the same period last year[12]. - The net profit attributable to shareholders of the listed company reached approximately ¥19.54 million, a significant increase of 103.52% year-on-year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥19.11 million, showing a remarkable increase of 2045.64% compared to the previous year[12]. - The net cash flow from operating activities was approximately ¥122.56 million, reflecting a growth of 120.02% year-on-year[12]. - The total assets of the company at the end of the reporting period amounted to approximately ¥3.07 billion, an increase of 8.81% from the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were approximately ¥1.67 billion, which is a slight increase of 1.31% compared to the end of the previous year[12]. - The basic earnings per share for the reporting period was ¥0.04, doubling from ¥0.02 in the same period last year[12]. - The diluted earnings per share increased to ¥0.07, up 40.00% from ¥0.05 in the previous year[12]. - The weighted average return on net assets was 1.18%, an increase of 0.64% compared to the previous year[12]. Product Sales and Market Expansion - The company's contrast agent products achieved sales revenue of CNY 279.81 million, representing a year-on-year growth of 10.85%[19]. - The sales revenue for the diabetes medication products reached CNY 66.73 million, with a significant year-on-year increase of 58.44%[20]. - The sales revenue of Jiuwei Zhenxin Granules was 68.58 million yuan, a year-on-year decrease of 17.24%[24]. - The company achieved significant revenue growth in overseas markets, with all contrast agent products successfully launched internationally[25]. - The company plans to enhance the market presence of Jiuwei Zhenxin Granules in Southeast Asia, with registration processes in Hong Kong and Thailand progressing as scheduled[23]. - The company is actively developing a series of health products around Jiuwei Zhenxin Granules to strengthen its brand influence in the anti-anxiety market[23]. - The company has established strategic partnerships with online healthcare platforms to expand the sales channels for Jiuwei Zhenxin Granules[22]. Acquisitions and Integrations - The acquisition of an 80% stake in Tianyuan Pharmaceutical has expanded the company's traditional Chinese medicine portfolio, adding 58 product approvals to its offerings[21]. - The company has successfully integrated Tianyuan Pharmaceutical into its consolidated financial statements starting from June 2024, enhancing its strategic layout in traditional Chinese medicine[16]. - The company completed the acquisition of 80% of Tianyuan Pharmaceutical for ¥202,000,000.00, holding an 80% stake, with the investment resulting in a loss of ¥1,127,281.25 during the reporting period[46]. - The company completed the acquisition of Tianyuan Pharmaceutical in June 2024, which has 58 traditional Chinese medicine approvals and generated nearly CNY 100 million in sales revenue for its core product in 2023[53]. Research and Development - The company’s R&D investment for the first half of 2024 was 35.45 million yuan, a decrease of 33.98% compared to the same period last year[27]. - The company has 34 projects in total under review or in development, an increase of 8 projects compared to the same period last year[26]. - The company has received approval for several new drug specifications, including Gadobutrol injection and Paroxetine enteric-coated sustained-release tablets[27]. - The company is focusing on a dual business model of chemical and traditional Chinese medicine to drive growth and expand its product line[29]. Financial Management and Investments - The company’s investment activities resulted in a net cash outflow of 461.02 million yuan, primarily due to the acquisition and purchase of financial products[42]. - The company reported a total of ¥839,000,000.00 in new financial assets purchased during the period, with ¥562,000,000.00 sold[47]. - The total amount of raised funds was ¥48,922.45 million, with ¥709.32 million invested during the reporting period, and a cumulative investment of ¥32,523.95 million[48]. - The company has a remaining unused amount of CNY 50.9115 million, which includes CNY 50.5668 million in raised funds[49]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[65]. - The company has received multiple environmental approvals for various projects, including a significant approval for a new R&D center in 2009[66]. - The company has undertaken various environmental impact reports for new production lines, including a project approved in January 2023 for iodine contrast agents[69]. - The company has implemented a self-monitoring plan for environmental pollutants, which is executed by a third-party testing company[75]. Corporate Governance and Shareholder Information - The company held its first extraordinary general meeting of 2024 on January 30, with a participation ratio of 19.22%[63]. - The annual general meeting for 2023 took place on May 13, with a participation ratio of 19.39%[63]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[63]. - The total number of common shareholders at the end of the reporting period is 28,527[90]. Risk Management - The company is actively monitoring industry policy changes and adjusting its operational strategies accordingly to mitigate risks from regulatory shifts[54]. - The company has established a robust risk management and control system for its R&D projects to ensure timely adjustments based on market conditions[58]. - The company emphasizes safety and environmental protection, having established comprehensive systems for managing safety and environmental risks in its production processes[59].

股票代码：300016 股票简称：北陆药业 公告编号：2024-051 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 第八届董事会第十九次会议决议公告 本报告已经公司第八届董事会审计委员会第十二次会议审议通过。 《2024 年半年度报告》及其摘要详见巨潮资讯网（www.cninfo.com.cn）等 中国证监会指定信息披露网站。《2024 年半年度报告披露提示性公告》及《2024 年半年度报告摘要》同时刊登在公司指定信息披露报刊：《中国证券报》、《证 券时报》及《上海证券报》。 具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）等中国证监会指定 信息披露网站披露的《2024 年半年度募集资金存放与使用情况的专项报告》。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第八届董事会第十九次 会议于2024年8月26日下午以现场及通讯相结合的方式召开，会议通知以邮件 方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参加表 决董事9人。本次会议的召集召开程序符合《公 ...

债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2024-052 报刊：《中国证券报》、《证券时报》及《上海证券报》。 表决结果：3票同意，0票反对，0票弃权。 二、2024年半年度募集资金存放与使用情况的专项报告 北京北陆药业股份有限公司 第八届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第八届监事会第十四次 会议于2024年8月26日下午以现场及通讯相结合的方式召开，会议通知以邮件 方式送达各位监事。本次会议应出席监事3人，实际出席监事3人，实际参加表 决监事3人。本次会议的召集召开程序符合《公司法》和《公司章程》的有关 规定。会议由监事会主席杨颖女士主持，与会监事以记名投票方式审议通过 了以下议案： 一、《2024年半年度报告》及其摘要 经审核，监事会认为：公司董事会编制和审核公司《2024年半年度报告》 及其摘要的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误 ...

证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年 7 月 25 日投资者关系活动记录表 编号：【2024】第 019 号 | --- | --- | --- | |------------|---------------|-------------| | | √特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | 参与单位名称 及人员姓名 首创证券：王斌 时 间 2024 年 7 月 25 日 地 点 公司会议室 上市公司接 待人员姓名 证券事务代表：孙志芳 Q1、天原药业产品及整合计划 天原药业拥有 58 个中药批文。其中：国家医保品种 44 个，国家 基药品种 18 个，OTC 品种 41 个，涉及清热解毒类、胃肠类、感冒类、 补益类、活血止痛类等多个领域；其核心产品金莲花颗粒系全国独家 品种、国家医保乙类、OTC 乙类，单品种全年收入近亿元，已覆盖全 国 31 个省。根据米内网数据显示，2023 年中国公立医疗机构终端清 投资者关 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 股票代码：300016 股票简称：北陆药业 公告编号：2024-046 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 第八届董事会第十八次会议决议公告 二○二四年七月十七日 北京北陆药业股份有限公司（以下简称"公司"）第八届董事会第十八次 会议于2024年7月17日上午以现场及通讯相结合的方式召开，会议通知以邮件 方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参加表 决董事9人。本次会议的召集召开程序符合《公司法》和《公司章程》的有关 规定。会议由董事长王旭先生主持，与会董事以记名投票方式审议通过了《关 于不向下修正北陆转债转股价格的议案》。 2 表决结果：9 票同意，0 票反对，0 票弃权。 特此公告。 北京北陆药业股份有限公司 董事会 根据《深圳证券交易所创业板股票上市规则》等相关规定和《北京北陆药 业股份有限公司向不特定对象发行可转换公司债券募集说明书》的有关约定， 自2024年6月27日至2024年7月17日，公司股票已出现在任意连续三十个交易日 中至少有十五个 ...

债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2024-045 北京北陆药业股份有限公司 关于不向下修正北陆转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会证监许可〔2020〕2810号文同意注册，公司于 1 2020年12月7日向不特定对象发行500万张可转换公司债券，每张面值100元， 发行总额50,000.00万元。 经深圳证券交易所同意，公司50,000.00万元可转换公司债券于2020年12 月28日起在深交所挂牌交易，债券简称"北陆转债"，债券代码"123082"。 （二）可转债转股期限 根据《北京北陆药业股份有限公司向不特定对象发行可转换公司债券募集 说明书》（以下简称"《募集说明书》"）的约定，公司本次发行的可转债转 股期自可转债发行结束之日起满六个月后的第一个交易日起至可转债到期日 止，即2021年6月11日至2026年12月6日（如遇法定节假日或休息日延至其后的 第一个工作日；顺延期间付息款项不另计息）。 （三）可转债转股价格调整情况 ...

证券代码:300016 证券简称:北陆药业 债券代码:123082 债券简称:北陆转债 2024 年 7 月 16 日投资者关系活动记录表 编号:【2024】第 018 号 | --- | --- | --- | |------------|---------------|-------------| | | √特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | 淳厚基金:张传植 国信自营:章耀 国联证券:王璐 财通基金:罗晓倩 华泰自营:詹寿明 国信资管:刘越 参与单位名称 华夏久盈:张伟光 国联证券:许津华 及人员姓名 中邮基金:李欣 海通期货资管:周水松 中金资管:蔡亦桐 财信证券:桓朝娜 第一创业自营:孙文 国联安基金:陈群 时 间 2024 年 7 月 16 日 地 点 —— 上市公司接 待人员姓名 证券事务代表:孙志芳 Q1、金莲花颗粒未来的市场空间 天原药业的金莲花颗粒这一核心产品,具有显著的市场潜力和增 长空间。公司在医药营销、研发、供应链管理等领域拥有深厚的经验 和资 ...

股票代码：300016 股票简称：北陆药业 公告编号：2024-044 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于北陆转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300016 证券简称：北陆药业 2、债券代码：123082 债券简称：北陆转债 3、转股价格：人民币 8.68 元/股 4、转股时间：2021 年 6 月 11 日至 2026 年 12 月 6 日 5、根据《北京北陆药业股份有限公司向不特定对象发行可转换公司债券 募集说明书》（以下简称"《募集说明书》"）的规定：在本可转债存续期间，当 公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格低于当 期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交公 司股东大会表决。 自 2024 年 6 月 27 日至 2024 年 7 月 10 日，公司股票已有十个交易日的 收盘价低于当期转股价格（8.68 元/股）的 85%（即 7.38 元/股），预计后续将 可能触发"北陆转债 ...

Strategic Development - The company aims to become one of the "Top 100 Pharmaceutical Manufacturing Enterprises in China" with a dual-driven business model of "chemical drugs + traditional Chinese medicine" [3] - The company has completed the acquisition of 80% equity of Tianyuan Pharmaceutical, making it an important subsidiary of Beilu Pharmaceutical [3] - The company is focusing on expanding its traditional Chinese medicine (TCM) sector, with the construction of the Bozhou production base as a key strategic layout [3] R&D and Innovation - In 2023, the company's R&D investment reached 122.3289 million yuan, a year-on-year increase of 22.62% [3] - The company is actively developing new products in areas such as contrast agents, central nervous system, endocrine, digestive system, and external preparations [3] - The company is strengthening R&D cost management and improving R&D efficiency to lay a solid foundation for long-term development [3] Production and Operations - The Bozhou production base, which started construction in March 2024, will enhance production capacity for granules, tablets, capsules, and pills [3] - The company is integrating Tianyuan Pharmaceutical into its operational system through collaboration in production, marketing, procurement, and finance [2] - The company is leveraging its marketing system, including in-hospital self-operation, agency, retail, and e-commerce channels, to expand market share [2] Market Expansion and Product Potential - The company sees significant market potential for Tianyuan Pharmaceutical's core product, Jinlianhua Granules, and aims to increase its market share [2] - The company is committed to building the "First Brand of Anti-Anxiety" with its exclusive TCM product, Jiuwei Zhenxin Granules [3] - The company expects the integration and synergy with Tianyuan Pharmaceutical to drive future market growth and profitability [2]